Literature DB >> 23439635

Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.

Helen Giamarellou1, Lambrini Galani, Fotini Baziaka, Ilias Karaiskos.   

Abstract

Ertapenem plus doripenem or meropenem were given in three patients suffering from pandrug-resistant, KPC-2-positive Klebsiella pneumoniae bacteremia (2 patients) and urinary tract infection (1 patient), respectively. All responded successfully, without relapse at follow-up. The results obtained should probably be attributed to ertapenem's increased affinity for the carbapenemases hindering doripenem/meropenem degradation in the environment of the microorganism.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23439635      PMCID： PMC3632902          DOI： 10.1128/AAC.02399-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.

Authors:  F Kontopidou; D Plachouras; E Papadomichelakis; G Koukos; I Galani; G Poulakou; G Dimopoulos; A Antoniadou; A Armaganidis; H Giamarellou
Journal:  Clin Microbiol Infect       Date:  2011-09-21       Impact factor: 8.067

Review 2.  Metallo-β-lactamases: a last frontier for β-lactams?

Authors:  Giuseppe Cornaglia; Helen Giamarellou; Gian Maria Rossolini
Journal:  Lancet Infect Dis       Date:  2011-05       Impact factor: 25.071

3.  Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

4.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

5.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 6.  Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria.

Authors:  M Akova; G L Daikos; L Tzouvelekis; Y Carmeli
Journal:  Clin Microbiol Infect       Date:  2012-05       Impact factor: 8.067

7.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

8.  An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10).

Authors:  Panagiota Giakkoupi; Costas C Papagiannitsis; Vivi Miriagou; Olga Pappa; Michalis Polemis; Kyriaki Tryfinopoulou; Leonidas S Tzouvelekis; Alkiviadis C Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2011-05-04       Impact factor: 5.790

Review 9.  Carbapenem resistance in Enterobacteriaceae: here is the storm!

Authors:  Patrice Nordmann; Laurent Dortet; Laurent Poirel
Journal:  Trends Mol Med       Date:  2012-04-03       Impact factor: 11.951

Review 10.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132
View more
  49 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

2.  Every cloud has a silver lining.

Authors:  Filippo Pieralli; Silvia Baroncelli; Alberto Farese; Antonio Mancini; Fabio Luise; Lucia Sammicheli; Alessandro Bartoloni; Gian Maria Rossolini; Carlo Nozzoli
Journal:  Intern Emerg Med       Date:  2017-05-10       Impact factor: 3.397

Review 3.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

4.  Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Authors:  M Souli; I Karaiskos; A Masgala; L Galani; E Barmpouti; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

Review 5.  Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello
Journal:  Virulence       Date:  2017-02-08       Impact factor: 5.882

Review 6.  Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.

Authors:  Vindana Chibabhai; Trusha Nana; Norma Bosman; Teena Thomas; Warren Lowman
Journal:  Infection       Date:  2017-09-15       Impact factor: 3.553

Review 7.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

8.  Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Jose F Camargo; Jacques Simkins; Thiago Beduschi; Akin Tekin; Laura Aragon; Armando Pérez-Cardona; Clara E Prado; Michele I Morris; Lilian M Abbo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-10       Impact factor: 5.191

9.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.